Genotypic resistance of archived and circulating viral strains in the blood of treated HIV-infected individuals

Journal of Acquired Immune Deficiency Syndromes

Volumn 44, Issue 5, 2007, Pages 518-524

  Turriziani, Ombretta ^a   Bucci, Mauro ^a   Stano, Armando ^a   Scagnolari, Carolina ^a   Bellomi, Francesca ^a   Fimiani, Caterina ^a   Mezzaroma, Ivano ^a   D'Ettorre, Gabriella ^a   Brogi, Andrea ^a   Vullo, Vincenzo ^a   Antonelli, Guido ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Drug resistance; HIV reservoirs; Peripheral blood mononuclear cell; Plasma

Indexed keywords

AMINO ACID; ANTIRETROVIRUS AGENT; CELL DNA; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

AMINO ACID SEQUENCE; ARTICLE; BLOOD SAMPLING; COMPARATIVE STUDY; CONTROLLED STUDY; EVALUATION; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRACELLULAR SPACE; MUTATIONAL ANALYSIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS STRAIN;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GENES, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; RNA, VIRAL; VIREMIA;

EID: 34247120521     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3180315515     Document Type: Article

References (37)

1. Palelle FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
2. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278:1295-1300.
3. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5:512-517.
4. Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med. 1999;340:1614-1622.
5. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med. 1999;340:1605-1613.
6. Lambotte O, Taoufik Y, de Goer MG, et al. Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2000;23:114-119.
7. Wang YM, Dyer WB, Wokman C, et al. Molecular evidence for drug-induced compartmentalization of HIV-1 quasispecies in a patient with periodic changes to HAART. AIDS. 2000;14:2265-2272.
8. Paolucci S, Baldanti F, Campanini G, et al. Analysis of HIV drug-resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment-naive and HAART patients. J Med Virol. 2001;65:207-217.
9. Ruff CT, Ray SC, Kwon P, et al. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J Virol. 2002;76:9481-9492.
10. Venturi G, Romano L, Carli T, et al. Divergent distribution of HIV-1 drug-resistant variants on and off antiretroviral therapy. Antivir Ther. 2002;7:245-250.
11. Bi X, Gatanaga H, Ida S, et al. Emergence of protease inhibitor resistance-associated mutations in plasma HIV-1 precedes that in proviruses of peripheral blood mononuclear cells by more than a year. J Acquir Immune Defic Syndr. 2003;34:1-6.
12. Sarmati L, Nicastri E, Uccella I, et al. Drug-associated resistance mutations in plasma and in peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected patients for whom highly active antiretroviral therapy is failing. J Clin Microbiol. 2003;41:1760-1762.
13. Lambotte O, Chaix ML, Gubler B, et al. The lymphocytes HIV reservoir in patients on long-term HAART is a memory of virus evolution. AIDS. 2004;18:1147-1158.
14. Verhofstede C, Noe A, Demecheleer E, et al. Drug-resistant variants that evolve during nonsuppressive therapy persist in HIV-1 infected peripheral blood mononuclear cells after long-term highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2004;35:473-483.
15. Antonelli G, Simeoni E, Turriziani O, et al. Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-α therapy. J Interferon Cytokine Res. 1999;19:243-251.
16. Lederberg B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA. 1999;282:2220-2226.
17. De Gruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther. 2000;5:41-48.
18. Clavel F, Hance AJ. Medical progress: HIV drug resistance. N Engl J Med. 2004;350:1023-1035.
19. Chew CB, Potter SJ, Wang B, et al. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART. J Clin Virol. 2005;33:206-216.
20. Devereux HL, Loveday C, Youle M, et al. Substantial correlation between HIV type 1 drug-associated resistance mutations in plasma and peripheral blood mononuclear cells in treatment experienced patients. AIDS Res Hum Retroviruses. 2000;16:1025-1030.
21. Kaye S, Comber E, Tenant-Flowers M, et al. The appearance of drug-resistance-associated point mutations in HIV type 1 plasma RNA precedes their appearance in proviral DNA. AIDS Res Hum Retroviruses. 1995;11:1221-1225.
22. Gazzard BG, Pozniak AL, Resenbaum W, et al. An open-label assessment of TMC125 a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS. 2003;17:49-54.
23. Devereux HL, Emery VC, Johnson MA, et al. Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations. J Med Virol. 2001;65:218-224.
24. Boucher CA, O'Sullivan E, Mulder JW, et al. Order appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis. 1992;165:105-110.
25. de Jong MD, Veenstra J, Stilianakis NI, et al. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency type 1 RNA load suppression by zidovudine. Proc Natl Acad Sci USA. 1996;93:5501-5506.
26. Devereux HL, Youle M, Johnson MA, et al. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS. 1999;13 (Suppl):F123-F127.
27. Verhofstede C, Wanzeele F, Van Der Gucht B, et al. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strain with a reverse transcriptase inhibitor-sensitive genotype. AIDS. 1999;13:2541-2546.
28. Deeks SG, Wrin T, Liegler T, et al. Virological and immunological consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 2001;344:472-480.
29. Boucher CA, Cammack N, Schipper P, et al. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 1993;37:2231-2234.
30. Tisdale M, Kemp SD, Parry NR, et al. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA. 1993;90:5653-5656.
31. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 1995;171:1411-1419.
32. Wainberg MA, Salomon H, Gu Z, et al. Development of HIV-1 resistance to (-)2′-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS. 1995;9:351-357.
33. Miller V, Sabin C, Hertogs K, et al. Virological and immunological effects of treatment interruption in HIV-1 infected patients with treatment failure. AIDS. 2000;14:2857-2867.
34. Isopet J, Massip P, Souyris C, et al. Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen. AIDS. 2000;14:2247-2255.
35. Deeks SG, Wrin T, Liegler T, et al. Virological and immunological consequences of discontinuing combination antiretroviral drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 2001;344:472-480.
36. De La Rosa R, Ruiz-Mateos E, Rubino A, et al. Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy. J Antimicrob Chemother. 2004;53:95-101.
37. Potter SJ, Lemey P, Dyer WB, et al. Genetic analyses reveal structured HIV-1 populations in serially sampled T lymphocytes of patients receiving HAART. Virology. 2006;348:35-46.